(Q34385474)

1 August 2017

1 reference

title

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide (English)

1 reference

1 August 2017

1 reference

1 reference

Indravadan H Patel

1

1 reference

1 August 2017

Xiaoping Zhang

2

1 reference

1 August 2017

Keith Nieforth

3

1 reference

1 August 2017

Miklos Salgo

4

1 reference

1 August 2017

Neil Buss

5

1 reference

1 August 2017

publication date

1 January 2005

1 reference

Clinical Pharmacokinetics

1 August 2017

published in

1 reference

1 August 2017

volume

44

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

175-186

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544020-00003

1 August 2017

exact match

0 references

cites work

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

1 reference

12 December 2020

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients

1 reference

12 December 2020

Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients

1 reference

12 December 2020

ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team

1 reference

12 December 2020

Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.

1 reference

12 December 2020

A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience

1 reference

12 December 2020

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

1 reference

12 December 2020

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

12 December 2020

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

1 reference

12 December 2020

Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients

1 reference

12 December 2020

Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition

1 reference

12 December 2020

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy

1 reference

12 December 2020

A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.

1 reference

12 December 2020

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor

1 reference

12 December 2020

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

1 reference

12 December 2020

1 reference

12 December 2020

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients

1 reference

12 December 2020

Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity

1 reference

12 December 2020

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

12 December 2020

10.2165/00003088-200544020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1041005138

0 references

1 reference